207 related articles for article (PubMed ID: 32236870)
1. X-Linked Hypophosphataemic Rickets and Growth.
Santos Rodríguez F
Adv Ther; 2020 May; 37(Suppl 2):55-61. PubMed ID: 32236870
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological management of X-linked hypophosphataemia.
Imel EA; White KE
Br J Clin Pharmacol; 2019 Jun; 85(6):1188-1198. PubMed ID: 30207609
[TBL] [Abstract][Full Text] [Related]
3. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
[TBL] [Abstract][Full Text] [Related]
5. Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab.
Sandy JL; Simm PJ; Biggin A; Rodda CP; Wall CL; Siafarikas A; Munns CF
J Paediatr Child Health; 2022 May; 58(5):762-768. PubMed ID: 35426466
[TBL] [Abstract][Full Text] [Related]
6. X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management.
Baroncelli GI; Mora S
Front Endocrinol (Lausanne); 2021; 12():688309. PubMed ID: 34421819
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH).
Rothenbuhler A; Schnabel D; Högler W; Linglart A
Metabolism; 2020 Feb; 103S():153892. PubMed ID: 30928313
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with X-linked hypophosphatemic rickets during Covid-19 pandemic lockdown.
Baroncelli GI; Bertelloni S; Cosci O Di Coscio M; Tyutyusheva N; D'Elios S; Peroni D
J Pediatr Endocrinol Metab; 2021 Jul; 34(7):905-910. PubMed ID: 33887813
[TBL] [Abstract][Full Text] [Related]
9. Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets.
Harada D; Ueyama K; Oriyama K; Ishiura Y; Kashiwagi H; Yamada H; Seino Y
J Pediatr Endocrinol Metab; 2021 Jun; 34(6):791-798. PubMed ID: 33837680
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
[TBL] [Abstract][Full Text] [Related]
12. FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference.
Piketty ML; Brabant S; Souberbielle JC; Maruani G; Audrain C; Rothenbuhler A; Prié D; Linglart A
Clin Chem Lab Med; 2020 Oct; 58(11):e267-e269. PubMed ID: 32653872
[No Abstract] [Full Text] [Related]
13. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
Imel EA; Glorieux FH; Whyte MP; Munns CF; Ward LM; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Mao M; Chen CY; Skrinar A; San Martin J; Portale AA
Lancet; 2019 Jun; 393(10189):2416-2427. PubMed ID: 31104833
[TBL] [Abstract][Full Text] [Related]
14. High iFGF23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH.
Igaki JM; Yamada M; Yamazaki Y; Koto S; Izawa M; Ariyasu D; Suzuki E; Hasegawa H; Hasegawa Y
Endocr J; 2011; 58(8):647-55. PubMed ID: 21597229
[TBL] [Abstract][Full Text] [Related]
15. MAPK inhibition and growth hormone: a promising therapy in XLH.
Fuente R; Gil-Peña H; Claramunt-Taberner D; Hernández-Frías O; Fernández-Iglesias Á; Alonso-Durán L; Rodríguez-Rubio E; Hermida-Prado F; Anes-González G; Rubio-Aliaga I; Wagner C; Santos F
FASEB J; 2019 Jul; 33(7):8349-8362. PubMed ID: 30974062
[TBL] [Abstract][Full Text] [Related]
16. Burosumab for Pediatric X-Linked Hypophosphatemia.
Imel EA
Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
[TBL] [Abstract][Full Text] [Related]
17. Sex differences of burosumab in children with X-linked hypophosphataemic rickets.
Filler G; Tremblay O; Chen E; Huang SSH; Stein R
Pediatr Nephrol; 2023 Sep; 38(9):3183-3187. PubMed ID: 36542147
[TBL] [Abstract][Full Text] [Related]
18. X-linked hypophosphatemic rickets: an Italian experts' opinion survey.
Emma F; Cappa M; Antoniazzi F; Bianchi ML; Chiodini I; Eller Vainicher C; Di Iorgi N; Maghnie M; Cassio A; Balsamo A; Baronio F; de Sanctis L; Tessaris D; Baroncelli GI; Mora S; Brandi ML; Weber G; D'Ausilio A; Lanati EP
Ital J Pediatr; 2019 May; 45(1):67. PubMed ID: 31151476
[TBL] [Abstract][Full Text] [Related]
19. X-linked hypophosphatemia and growth.
Fuente R; Gil-Peña H; Claramunt-Taberner D; Hernández O; Fernández-Iglesias A; Alonso-Durán L; Rodríguez-Rubio E; Santos F
Rev Endocr Metab Disord; 2017 Mar; 18(1):107-115. PubMed ID: 28130634
[TBL] [Abstract][Full Text] [Related]
20. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
